With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition.

The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response rate among patients satisfying the criteria for high risk, including relapse within 24 months.

After talking at the ASH meeting, first author Juan Pablo Alderuccio, MD, Associate Professor of Medicine in the Sylvester Comprehensive Cancer Center’s Division of Hematology at the University of Miami School of Medicine, discussed his findings with OncTimesTalk correspondent Peter Goodwin.